This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;286:1308-1309.

	Since this article does not have an abstract, we have provided the first 145 words of the full text and any section headings.

MMWR. 2001;50:646

In April 2001, Pharmacia Corporation (Peapack, New Jersey) announced the discontinuation of its U.S. production of spectinomycin (Trobicin®)* and that its remaining inventory would expire on June 30, 2001.¹ Since then, examination of the inventory has revealed that, although some lots of the bacteriostatic water packaged with the spectinomycin have expired, the spectinomycin powder has a shelf-life beyond June 30. The Food and Drug Administration has approved Pharmacia's request to remove the bacteriostatic water and to relabel the current inventory of spectinomycin to expire on December 31. To obtain spectinomycin or to verify whether a spectinomycin lot may continue to be used, contact Wendy Johnson, Pharmacia Corporation, telephone (800) 976-7741, extension 30110; fax (800) 852-6421.

Pharmacia is planning to resume U.S. spectinomycin production later in 2001. When new spectinomycin is available, it will be distributed again through the usual wholesale distribution network.

*Use of trade names is for identification only and does not imply endorsement by CDC or the U.S. Department of Health and Human Services.

All MMWR references are available on the Internet at http://www.cdc.gov/mmwr. Use the search function to find specific articles.

REFERENCES

1. CDC. Shortage of spectinomycin—United States. MMWR. 2001;50:470.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?